How AFib treatment was worked out
Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
The irregular pulse was described long before anyone knew what caused it, and the explanation needed a machine that could see electricity in a living person.
The treatments arrived in a strange order: the stroke prevention came from spoiled hay, and the cure for the rhythm came from noticing where the signals started.
Related pages: Atrial fibrillation (AFib)
The bottom line
- The irregular pulse was described centuries before its cause was known.
- The ECG, developed around 1900, made the diagnosis possible.
- Warfarin came from an investigation into cattle bleeding to death.
- Pulmonary vein triggers were identified in the 1990s, which created modern ablation.
- The rate-versus-rhythm question took large trials to answer, and the answer has since been revised.
- How much of the early natural history was misattributed to other conditions.
- Why the rate-versus-rhythm answer changed with better tools.
The story, step by step
- 1. The pulse without a name ()
- 2. The machine that showed it ()
- 3. Spoiled hay and stroke prevention ()
- 4. Finding where it starts ()
What the evidence labels mean
Before 1900
What happens
Observed, not understood.
What the research shows
- Irregular pulses were described in ancient Chinese and later European medical writing, often with grim prognostic notes attached.
- In the 19th century clinicians distinguished a pulse that was irregular in a repeating way from one with no pattern at all, and linked the latter to a poor outcome.
- The term delirium cordis was used for this chaotic pulse. The mechanism was unknown.
- Fibrillation had been observed in animal hearts in the laboratory, but connecting that to the clinical pulse required a way to record electrical activity in a living person.
- Without that, treatment was limited to digitalis, prepared from foxglove and in use since the late 18th century, which slowed the pulse without anyone knowing why it helped.
- Digitalis, as digoxin, is still occasionally used for rate control today, which makes it one of the oldest drugs still in cardiac practice.
Why it matters
A treatment that works without an explanation is not unusual in medicine. Digitalis preceded the understanding of what it was treating by more than a century.
What's still uncertain
- How often early descriptions of irregular pulse were AFib.
Read more
- NHLBI: Atrial fibrillationGovernment
- MedlinePlus: Atrial fibrillationGovernment
1900s to 1920s
What happens
The ECG settles the question.
What the research shows
- Willem Einthoven developed the string galvanometer around 1900, producing the first practical electrocardiograms, and later received a Nobel Prize for it.
- In 1909 Thomas Lewis and Arthur Cushny independently recorded the human arrhythmia and identified it as atrial fibrillation, matching the clinical pulse to the laboratory phenomenon.
- The absent P wave and the irregular baseline became the diagnostic signature and remain so.
- Early machines required the patient to sit with limbs in buckets of saline solution and weighed hundreds of pounds.
- Over the following decades the ECG shrank, spread and became routine, which is what made AFib a diagnosable rather than merely describable condition.
- The link between AFib and stroke was recognised during this period but could not yet be acted on.
Why it matters
The diagnostic criteria established in 1909 are essentially the ones used on a modern ECG, which is unusual longevity for a medical test.
What's still uncertain
- How much AFib was misdiagnosed before the ECG.
Read more
- NHLBI: Atrial fibrillationGovernment
- MedlinePlus: ArrhythmiaGovernment
1920s to 1990s
What happens
An accident on the prairies.
What the research shows
- In the 1920s cattle in Canada and the northern United States began bleeding to death after minor injuries. The cause was traced to spoiled sweet clover hay.
- Karl Link's laboratory at Wisconsin isolated the anticoagulant responsible in 1940, and a more potent derivative was patented and named warfarin after the funding foundation.
- It was first sold as rat poison. Its use in people followed, and it became the mainstay of stroke prevention for decades.
- Trials in the late 1980s and early 1990s showed that warfarin substantially reduced stroke in AFib, which transformed the condition from a rhythm nuisance into a treatable stroke risk.
- Warfarin required frequent blood tests, had numerous interactions and was difficult to keep in range, which limited how many people actually received it.
- Direct oral anticoagulants, trialled against warfarin from around 2009 onward, removed most of that burden and became first-line for most people.
Why it matters
The single biggest change in AFib outcomes came not from fixing the rhythm but from preventing its most serious complication.
What's still uncertain
- How much of the remaining stroke burden is from undertreatment.
Read more
- MedlinePlus: Blood thinnersGovernment
- NHLBI: Atrial fibrillationGovernment
Next: Finding where it starts
1990s to today
What happens
Ablation becomes possible.
What the research shows
- Surgical treatment came first: James Cox developed the maze procedure in the late 1980s, cutting and sewing patterns into the atria to block the circuits. It worked, but required open-heart surgery.
- In 1998 Michel Haissaguerre and colleagues in Bordeaux reported that most AFib episodes were triggered by rapid firing from the pulmonary veins.
- That single observation redirected the field. If the triggers were in a few known places, they could be reached with a catheter.
- Pulmonary vein isolation became the standard ablation target, first point by point with radiofrequency, then with cryoballoons, and more recently with pulsed field ablation.
- The AFFIRM trial in 2002 compared rate and rhythm control and found no survival advantage to chasing normal rhythm with the drugs then available, which shaped practice for years.
- The EAST-AFNET 4 trial in 2020 found benefit from early rhythm control in recently diagnosed patients, partly because the available tools had improved. Practice shifted again.
Why it matters
The reversal between 2002 and 2020 is a reminder that trials answer the question with the tools of their time, not for all time.
What's still uncertain
- How durable modern ablation results will prove.
- Which patients should have ablation first-line.
Read more
- NHLBI: Atrial fibrillationGovernment
- American Heart Association: atrial fibrillationNonprofit